typical starting dose of tirzepatide Zepbound® Dosage Guide Tirzepatide Dosing - A Patient
Description
In 2025, the company reported a modest +0.99% YoY revenue growth, but the underlying story is more interesting: Dupixent ($17.8B) remains the clear growth engine, benefiting from expanding indications like COPD and broader patient reach, while the EYLEA franchise ($7.89B) continues to be a core contributor despite facing biosimilar pressure, supported by the transition to EYLEA HD, and Libtayo ($1.45B) is steadily gaining ground in oncology, particularly in lung cancer settings
G., CalleHerrero J., et al., Exercise Preserves Lean Mass and Performance During Severe Energy Deficit: The Role of Exercise Volume and Dietary Protein Content, Frontiers in Physiology 8 (2017): 483: [published Online First: 2017/08/10], 10.3389/fphys.2017.00483
Patients with type 2 diabetes treated with GLP-1 agonists demonstrated improved endothelial function and reduced arterial stiffnessmarkers closely linked to vascular inflammation
The basal forebrain cholinergic system in aging and dementia
